290 related articles for article (PubMed ID: 17315156)
1. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience.
Kantarjian HM; O'Brien S; Huang X; Garcia-Manero G; Ravandi F; Cortes J; Shan J; Davisson J; Bueso-Ramos CE; Issa JP
Cancer; 2007 Mar; 109(6):1133-7. PubMed ID: 17315156
[TBL] [Abstract][Full Text] [Related]
2. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP
Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis.
Liu W; Zhou Z; Chen L; Wang X
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e530-e544. PubMed ID: 33716056
[TBL] [Abstract][Full Text] [Related]
4. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
Issa JP; Garcia-Manero G; Huang X; Cortes J; Ravandi F; Jabbour E; Borthakur G; Brandt M; Pierce S; Kantarjian HM
Cancer; 2015 Feb; 121(4):556-61. PubMed ID: 25336333
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.
Quintás-Cardama A; Ravandi F; Liu-Dumlao T; Brandt M; Faderl S; Pierce S; Borthakur G; Garcia-Manero G; Cortes J; Kantarjian H
Blood; 2012 Dec; 120(24):4840-5. PubMed ID: 23071272
[TBL] [Abstract][Full Text] [Related]
6. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.
Lübbert M; Suciu S; Baila L; Rüter BH; Platzbecker U; Giagounidis A; Selleslag D; Labar B; Germing U; Salih HR; Beeldens F; Muus P; Pflüger KH; Coens C; Hagemeijer A; Eckart Schaefer H; Ganser A; Aul C; de Witte T; Wijermans PW
J Clin Oncol; 2011 May; 29(15):1987-96. PubMed ID: 21483003
[TBL] [Abstract][Full Text] [Related]
7. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities.
Ravandi F; Issa JP; Garcia-Manero G; O'Brien S; Pierce S; Shan J; Borthakur G; Verstovsek S; Faderl S; Cortes J; Kantarjian H
Cancer; 2009 Dec; 115(24):5746-51. PubMed ID: 19795507
[TBL] [Abstract][Full Text] [Related]
8. Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
Gao S; Li Z; Fu JH; Hu XH; Xu Y; Jin ZM; Tang XW; Han Y; Chen SN; Sun AN; Wu DP; Qiu HY
Asian Pac J Cancer Prev; 2015; 16(15):6627-32. PubMed ID: 26434886
[TBL] [Abstract][Full Text] [Related]
9. Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants.
Xie M; Jiang Q; Xie Y
Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):22-8. PubMed ID: 25042977
[TBL] [Abstract][Full Text] [Related]
10. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR
Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320
[TBL] [Abstract][Full Text] [Related]
11. A favorable inductive remission rate for decitabine combined with chemotherapy as a first course in <60-year-old acute myeloid leukemia patients with myelodysplasia syndrome features.
Liu F; Wang H; Liu J; Zhou Z; Zheng D; Huang B; Su C; Zou W; Xu D; Tong X; Li J
Cancer Med; 2019 Sep; 8(11):5108-5115. PubMed ID: 31322840
[TBL] [Abstract][Full Text] [Related]
12. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
Estey EH
Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301
[TBL] [Abstract][Full Text] [Related]
13. [The clinical safety and efficacy of low dose subcutaneous decitabine in treating acute myeloid leukemia and intermediate- or higer-risk myelodysplastic syndromes in the elderly patients].
Ai H; Wei XD; Yin QS; Wang P; Mi RH; Yuan FF; Chen L; Song YP
Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):606-609. PubMed ID: 28789495
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
Song LX; Xu L; Li X; Chang CK; Zhang Y; Wu LY; He Q; Zhang QX; Li X
Ann Hematol; 2012 Dec; 91(12):1879-86. PubMed ID: 22895556
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome.
Daver N; Kantarjian H; Ravandi F; Estey E; Wang X; Garcia-Manero G; Jabbour E; Konopleva M; O'Brien S; Verstovsek S; Kadia T; Dinardo C; Pierce S; Huang X; Pemmaraju N; Diaz-Pines-Mateo M; Cortes J; Borthakur G
Leukemia; 2016 Feb; 30(2):268-73. PubMed ID: 26365212
[TBL] [Abstract][Full Text] [Related]
17. [Clinical observation of decitabine-treating patients with myelodysplastic syndrome and acute myeloid leukemia].
Yang H; Zhu HY; Jiang MM; Wang QS; Han XP; Huang WR; Jing Y; Wang SH; Zhang SS; Mei JH; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):121-5. PubMed ID: 23484704
[TBL] [Abstract][Full Text] [Related]
18. The euphoria of hypomethylating agents in MDS and AML: is it justified?
Sekeres MA
Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
[TBL] [Abstract][Full Text] [Related]
19. Decitabine: An effective and safe treatment for myelodysplastic syndrome and acute myeloid leukemia.
Feng X; Chen X; Nie S; Chang Y; Meng F; Zhou J; Mao C; Li T; Yan X; Huang J; Liu S; Gao Y; Xiao S
J Cancer Res Ther; 2019; 15(7):1471-1476. PubMed ID: 31939424
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.
Jabbour E; Short NJ; Montalban-Bravo G; Huang X; Bueso-Ramos C; Qiao W; Yang H; Zhao C; Kadia T; Borthakur G; Pemmaraju N; Sasaki K; Estrov Z; Cortes J; Ravandi F; Alvarado Y; Komrokji R; Sekeres MA; Steensma DP; DeZern A; Roboz G; Kantarjian H; Garcia-Manero G
Blood; 2017 Sep; 130(13):1514-1522. PubMed ID: 28774880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
